|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
US6218525B1
(en)
|
1988-02-25 |
2001-04-17 |
The General Hospital Corporation |
Nucleic acid encoding CD28
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6685941B1
(en)
|
1988-11-23 |
2004-02-03 |
The Regents Of The University Of Michigan |
Methods of treating autoimmune disease via CTLA-4Ig
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US6291159B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
|
US6641809B1
(en)
|
1990-03-26 |
2003-11-04 |
Bristol-Myers Squibb Company |
Method of regulating cellular processes mediated by B7 and CD28
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
US7063943B1
(en)
|
1990-07-10 |
2006-06-20 |
Cambridge Antibody Technology |
Methods for producing members of specific binding pairs
|
|
DE69129154T2
(de)
|
1990-12-03 |
1998-08-20 |
Genentech, Inc., South San Francisco, Calif. |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
|
US5871907A
(en)
|
1991-05-15 |
1999-02-16 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
EP0940468A1
(en)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Humanized antibody variable domain
|
|
US5844095A
(en)
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
|
KR100238712B1
(ko)
|
1991-06-27 |
2000-01-15 |
스티븐 비. 데이비스 |
씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
US6887471B1
(en)
*
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
US5773253A
(en)
|
1993-01-22 |
1998-06-30 |
Bristol-Myers Squibb Company |
MYPPPY variants of CTL A4 and uses thereof
|
|
US6482919B2
(en)
|
1993-02-01 |
2002-11-19 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
|
US5942607A
(en)
|
1993-07-26 |
1999-08-24 |
Dana-Farber Cancer Institute |
B7-2: a CTLA4/CD28 ligand
|
|
US6084067A
(en)
|
1993-07-26 |
2000-07-04 |
Dana-Farber Cancer Institute |
CTLA4/CD28 ligands and uses therefor
|
|
US6130316A
(en)
|
1993-07-26 |
2000-10-10 |
Dana Farber Cancer Institute |
Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
|
|
US6218510B1
(en)
|
1994-03-02 |
2001-04-17 |
Brigham & Woman's Hospital |
B7-1 and B7-2 polypeptides
|
|
US6713279B1
(en)
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
|
CA2279547A1
(en)
|
1997-01-31 |
1998-08-06 |
University Of Rochester |
Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
|
|
US6294170B1
(en)
|
1997-08-08 |
2001-09-25 |
Amgen Inc. |
Composition and method for treating inflammatory diseases
|
|
US6730512B2
(en)
|
1997-04-09 |
2004-05-04 |
Amdl, Inc. |
Combination immunogene therapy
|
|
ATE282092T1
(de)
|
1997-06-11 |
2004-11-15 |
Borean Pharma As |
Trimerisierendes modul
|
|
US6165476A
(en)
|
1997-07-10 |
2000-12-26 |
Beth Israel Deaconess Medical Center |
Fusion proteins with an immunoglobulin hinge region linker
|
|
US5891432A
(en)
|
1997-07-29 |
1999-04-06 |
The Immune Response Corporation |
Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
|
|
DE69937291T2
(de)
|
1998-04-02 |
2008-07-10 |
Genentech, Inc., South San Francisco |
Antikörpervarianten und fragmente davon
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9823071D0
(en)
|
1998-10-21 |
1998-12-16 |
Affibody Technology Ab |
A method
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
KR101077001B1
(ko)
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
US8624010B1
(en)
|
1999-02-03 |
2014-01-07 |
Steven K. Yoshinaga |
Nucleic acids encoding B7RP1
|
|
EP1173204B1
(en)
|
1999-04-30 |
2010-04-21 |
The Trustees Of The University Of Pennsylvania |
Mutant human cd80 and compositions for and methods of making and using the same
|
|
GB9917027D0
(en)
|
1999-07-20 |
1999-09-22 |
Affibody Technology Sweeden Ab |
In vitro selection and optional identification of polypeptides using solid support carriers
|
|
EP1218504B1
(en)
|
1999-09-21 |
2007-07-11 |
Genetics Institute, LLC |
Gl50 molecules and uses therefor
|
|
WO2001049318A1
(en)
|
2000-01-03 |
2001-07-12 |
Tr Associates, L.L.C. |
Novel chimeric proteins and methods for using the same
|
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
US7094874B2
(en)
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
|
CN101255192A
(zh)
|
2000-05-26 |
2008-09-03 |
布里斯托尔-迈尔斯斯奎布公司 |
可溶性ctla4突变体分子及其应用
|
|
US7183376B2
(en)
*
|
2000-06-23 |
2007-02-27 |
Maxygen, Inc. |
Variant B7 co-stimulatory molecules
|
|
US7094875B2
(en)
|
2000-06-23 |
2006-08-22 |
Maxygen, Inc. |
Co-stimulatory polypeptides
|
|
AU7309601A
(en)
|
2000-06-28 |
2002-01-08 |
Genetics Inst |
Pd-l2 molecules: novel pd-1 ligands and uses therefor
|
|
HRP20030071B1
(hr)
|
2000-07-03 |
2014-01-03 |
Bristol-Myers Squibb Company |
Postupci za lijeäśenje reumatskih bolesti uporabom topljivih ctla4 mutantnih molekula
|
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
|
US6635750B1
(en)
|
2000-07-20 |
2003-10-21 |
Millennium Pharmaceuticals, Inc. |
B7-H2 nucleic acids, members of the B7 family
|
|
MXPA03010568A
(es)
|
2001-05-23 |
2005-03-07 |
Squibb Bristol Myers Co |
Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles.
|
|
AU2002368044A1
(en)
|
2001-06-22 |
2004-04-19 |
Maxygen, Inc. |
Co-stimulatory molecules
|
|
NZ530451A
(en)
|
2001-06-29 |
2008-04-30 |
Univ Leland Stanford Junior |
TIM gene sequences and their use in immunological disorders and cancer
|
|
KR100453877B1
(ko)
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
|
CA2466279A1
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
|
US7235631B2
(en)
|
2002-02-07 |
2007-06-26 |
Mayo Foundation For Medical Education And Research |
ICOS mutants
|
|
EP1553966B1
(en)
|
2002-10-03 |
2012-08-01 |
Wyeth Holdings Corporation |
Fusion peptides comprising the human papillomavirus e7 and e6 polypeptides and immunogenic compositions thereof
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
ES2347241T3
(es)
|
2002-12-16 |
2010-10-27 |
Genentech, Inc. |
Variantes de inmunoglobulina y sus utilizaciones.
|
|
DE60335024D1
(de)
|
2002-12-23 |
2010-12-30 |
Bristol Myers Squibb Co |
Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
|
|
US7563869B2
(en)
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
|
AU2004264901B2
(en)
|
2003-08-04 |
2009-12-10 |
Bristol-Myers Squibb Company |
Methods for treating cardiovascular disease using a soluble CTLA4 molecule
|
|
US8778880B2
(en)
|
2004-02-02 |
2014-07-15 |
Ambrx, Inc. |
Human growth hormone modified at position 35
|
|
CN1942483B
(zh)
|
2004-04-13 |
2012-09-26 |
弗·哈夫曼-拉罗切有限公司 |
抗p型选凝素抗体
|
|
CN103172731A
(zh)
|
2004-07-15 |
2013-06-26 |
赞科股份有限公司 |
优化的Fc变体
|
|
US7638299B2
(en)
|
2004-07-21 |
2009-12-29 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
NZ555353A
(en)
|
2004-11-22 |
2009-12-24 |
Anaphore Inc |
TNF antagonists
|
|
MX2007007590A
(es)
|
2004-12-22 |
2007-12-10 |
Ambrx Inc |
Composiciones que contienen, metodos que involucran y usos de aminoacidos no naturales y polipeptidos.
|
|
CN101198347A
(zh)
|
2005-04-06 |
2008-06-11 |
布里斯托尔-迈尔斯斯奎布公司 |
使用可溶性ctla4突变型分子治疗与移植物移植有关的免疫病症的方法
|
|
HRP20110404T1
(hr)
|
2005-11-08 |
2011-08-31 |
Ambrx |
Ubrzivači za modifikaciju ne-prirodnih aminokiselina i polipeptida ne-prirodnih aminokiselina
|
|
AU2006330922B2
(en)
|
2005-12-20 |
2012-07-26 |
Bristol-Myers Squibb Company |
Compositions and methods for producing a composition
|
|
DK2615108T3
(en)
|
2006-09-08 |
2017-01-30 |
Ambrx Inc |
Modified human plasma polypeptide or fc scaffolds and their applications
|
|
GB0620934D0
(en)
|
2006-10-20 |
2006-11-29 |
Cambridge Antibody Tech |
Protein variants
|
|
US8907065B2
(en)
|
2006-12-15 |
2014-12-09 |
Ablynx N.V. |
Polypeptides that modulate the interaction between cells of the immune system
|
|
DK2141997T3
(da)
|
2007-03-30 |
2013-02-11 |
Sloan Kettering Inst Cancer |
Konstitutiv ekspression af co-stimulatoriske ligander på adoptivt overførte t-lymfocytter
|
|
EP2076533B1
(en)
|
2007-05-02 |
2014-10-08 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
|
CN101784564B
(zh)
|
2007-07-13 |
2014-07-02 |
约翰霍普金斯大学 |
B7-dc变体
|
|
CN101998965B
(zh)
|
2007-11-01 |
2014-03-12 |
安斯泰来制药有限公司 |
免疫抑制性多肽与核酸
|
|
US11260133B2
(en)
|
2008-02-21 |
2022-03-01 |
Sanford-Burnham Medical Research Institute |
Methods and compositions related to peptides and proteins with C-terminal elements
|
|
WO2009117622A2
(en)
|
2008-03-19 |
2009-09-24 |
Ambrx, Inc. |
Modified fgf-23 polypeptides and their uses
|
|
HUE036780T2
(hu)
|
2008-04-09 |
2018-07-30 |
Genentech Inc |
Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére
|
|
US7915222B2
(en)
|
2008-05-05 |
2011-03-29 |
Bristol-Myers Squibb Company |
Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
|
|
DK2285980T3
(en)
|
2008-06-02 |
2017-08-28 |
Roussy Inst Gustave |
NATURAL KILLER p30 (NKp30) DYSFUNCTION AND THE BIOLOGICAL APPLICATIONS THEREOF
|
|
US9931386B2
(en)
|
2008-06-16 |
2018-04-03 |
Atsuo Ochi |
Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
|
|
PL2318029T3
(pl)
|
2008-07-23 |
2018-03-30 |
Elanco Us Inc. |
Zmodyfikowane polipeptydy bydlęcego G-CSF i ich zastosowania
|
|
EP2328920A2
(en)
|
2008-08-25 |
2011-06-08 |
Amplimmune, Inc. |
Targeted costimulatory polypeptides and methods of use to treat cancer
|
|
RS54233B1
(sr)
|
2008-08-25 |
2015-12-31 |
Amplimmune Inc. |
Kompozicije pd-1 antagonista i postupci za njihovu primenu
|
|
US8278418B2
(en)
|
2008-09-26 |
2012-10-02 |
Ambrx, Inc. |
Modified animal erythropoietin polypeptides and their uses
|
|
MX2011008190A
(es)
|
2009-02-04 |
2011-10-06 |
Univ Texas |
Direccionamiento dual de mir-208 y mir-499 en el tratamiento de trastornos cardiacos.
|
|
US8840889B2
(en)
*
|
2009-08-13 |
2014-09-23 |
The Johns Hopkins University |
Methods of modulating immune function
|
|
EP2482849B1
(en)
|
2009-09-30 |
2018-06-06 |
Memorial Sloan-Kettering Cancer Center |
Combination immunotherapy for the treatment of cancer
|
|
US9540426B2
(en)
|
2009-10-06 |
2017-01-10 |
Bristol-Myers Squibb Company |
Mammalian cell culture processes for protein production
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
WO2011097477A1
(en)
|
2010-02-04 |
2011-08-11 |
The Trustees Of The University Of Pennsylvania |
Icos critically regulates the expansion and function of inflammatory human th17 cells
|
|
HUE050768T2
(hu)
|
2010-02-19 |
2021-01-28 |
Xencor Inc |
Új CTLA4-IG immunadhezinek
|
|
CA3253628A1
(en)
|
2010-03-05 |
2025-11-29 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
US8642557B2
(en)
|
2010-03-12 |
2014-02-04 |
Abbvie Biotherapeutics Inc. |
CTLA4 proteins and their uses
|
|
CN107090029B
(zh)
|
2010-11-11 |
2021-07-13 |
港大科桥有限公司 |
可溶性 pd-1变体、融合构建体及其用途
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
EP2697257B1
(en)
|
2011-04-13 |
2016-10-19 |
Bristol-Myers Squibb Company |
Fc fusion proteins comprising novel linkers or arrangements
|
|
KR20140029446A
(ko)
|
2011-04-15 |
2014-03-10 |
컴퓨젠 엘티디. |
면역 관련 장애 및 암의 치료를 위한 폴리펩티드 및 폴리뉴클레오티드, 및 이들의 용도
|
|
CN107519486B
(zh)
|
2011-06-24 |
2021-06-11 |
台北荣民总医院 |
于感染性与恶性疾病的治疗中提升免疫反应的方法
|
|
CN107988156B
(zh)
*
|
2011-06-30 |
2022-01-04 |
建新公司 |
T细胞活化的抑制剂
|
|
US8956619B2
(en)
|
2011-10-25 |
2015-02-17 |
University Of Maryland, Baltimore County |
Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
|
|
KR101981873B1
(ko)
|
2011-11-28 |
2019-05-23 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
CN104302408B
(zh)
|
2012-02-27 |
2016-12-14 |
阿穆尼克斯运营公司 |
Xten缀合组合物和制造其的方法
|
|
US9758566B2
(en)
|
2012-03-29 |
2017-09-12 |
The General Hospital Corporation |
Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
|
|
KR102133060B1
(ko)
|
2012-05-11 |
2020-07-10 |
메디뮨 리미티드 |
Ｃｔｌａ－４ 변이체
|
|
JP2015520192A
(ja)
|
2012-06-06 |
2015-07-16 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Ｈｉｐｐｏ経路を調節する結合剤およびその使用
|
|
WO2014004857A1
(en)
|
2012-06-27 |
2014-01-03 |
Orban Biotech Llc |
Ctla4 fusion proteins for the treatment of diabetes
|
|
JP5857896B2
(ja)
|
2012-07-06 |
2016-02-10 |
東京エレクトロン株式会社 |
成膜装置の運転方法及び成膜装置
|
|
KR20150090919A
(ko)
|
2012-12-04 |
2015-08-06 |
온코메드 파마슈티칼스, 인크. |
결합제를 사용한 면역요법
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
WO2014138188A1
(en)
|
2013-03-07 |
2014-09-12 |
The General Hospital Corporation |
Human ctla4 mutants and use thereof
|
|
US20160271218A1
(en)
|
2013-06-27 |
2016-09-22 |
Mor Research Applications Ltd. |
Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease
|
|
GB201311475D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Polypeptides
|
|
AU2014290069B2
(en)
|
2013-07-16 |
2019-01-03 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
|
|
KR20160113268A
(ko)
|
2014-01-28 |
2016-09-28 |
베이징 한미 파마슈티컬 컴퍼니 리미티드 |
이기능 융합단백질,이의 제조방법 및 용도
|
|
EP3105333B1
(en)
|
2014-02-10 |
2020-04-08 |
Emory University |
Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
|
|
US20170042972A1
(en)
|
2014-04-25 |
2017-02-16 |
Chetan KARYEKAR |
Use of ctla4 compound for achieving drug-free remission in subjects with early ra
|
|
JP2017522311A
(ja)
|
2014-07-16 |
2017-08-10 |
ジェネンテック， インコーポレイテッド |
Ｔｉｇｉｔ阻害剤及び抗癌剤を使用する癌の治療方法
|
|
DK3552615T3
(da)
|
2014-07-16 |
2022-02-14 |
Transgene |
Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
|
|
HRP20201153T1
(hr)
|
2014-08-08 |
2021-01-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Pd-1 sredstva visokog afiniteta i načini uporabe
|
|
KR102812180B1
(ko)
|
2014-09-03 |
2025-05-23 |
버베리안 노딕 에이/에스 |
재조합 변형된 백시니아 바이러스 앙카라 (mva) 필로바이러스 백신
|
|
US20160145344A1
(en)
|
2014-10-20 |
2016-05-26 |
University Of Southern California |
Murine and human innate lymphoid cells and lung inflammation
|
|
AU2015343048A1
(en)
|
2014-11-06 |
2017-05-18 |
Children's Research Institute, Children's National Medical Center |
Immunotherapeutics for cancer and autoimmune diseases
|
|
WO2016118577A1
(en)
|
2015-01-22 |
2016-07-28 |
Medimmune, Llc |
Thymosin-beta-four fusion proteins
|
|
JP6841812B2
(ja)
|
2015-04-02 |
2021-03-10 |
キャンキュア リミティド |
免疫応答を惹起するための作用物質及び組成物
|
|
WO2016164428A1
(en)
|
2015-04-06 |
2016-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
|
|
EP3283508B1
(en)
|
2015-04-17 |
2021-03-17 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins with tunable affinities
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
UY36687A
(es)
|
2015-05-29 |
2016-11-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Anticuerpos contra ox40 y sus usos
|
|
HUE055207T2
(hu)
|
2015-07-30 |
2021-11-29 |
Macrogenics Inc |
PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására
|
|
CA2993429A1
(en)
|
2015-07-31 |
2017-02-09 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immuno-oncology therapies
|
|
AU2016303485A1
(en)
|
2015-07-31 |
2018-03-01 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immunomodulation
|
|
WO2017029389A1
(en)
|
2015-08-20 |
2017-02-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
B7-h1 fusion polypeptides for treating and preventing organ failure
|
|
AU2016323069A1
(en)
|
2015-09-14 |
2018-04-12 |
Alpine Immune Sciences, Inc. |
Tunable variant immunoglobulin superfamily domains and engineered cell therapy
|
|
SG10201912943RA
(en)
|
2015-10-02 |
2020-02-27 |
Symphogen As |
Anti-pd-1 antibodies and compositions
|
|
CA3001131A1
(en)
|
2015-11-02 |
2017-05-11 |
Five Prime Therapeutics, Inc. |
Cd80 extracellular domain polypeptides and their use in cancer treatment
|
|
TWI705972B
(zh)
|
2015-11-04 |
2020-10-01 |
臺北榮民總醫院 |
惡性病變的組合治療
|
|
EA201891178A1
(ru)
|
2015-12-14 |
2019-01-31 |
Макродженикс, Инк. |
Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
|
|
US20190062400A1
(en)
|
2016-03-02 |
2019-02-28 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
SG11201808457PA
(en)
|
2016-04-15 |
2018-10-30 |
Alpine Immune Sciences Inc |
Icos ligand variant immunomodulatory proteins and uses thereof
|
|
US11078282B2
(en)
|
2016-04-15 |
2021-08-03 |
Alpine Immune Sciences, Inc. |
CD80 variant immunomodulatory proteins and uses thereof
|
|
CN110088127A
(zh)
|
2016-07-28 |
2019-08-02 |
高山免疫科学股份有限公司 |
Cd155变体免疫调节蛋白及其用途
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
PE20240950A1
(es)
|
2016-10-14 |
2024-05-06 |
Xencor Inc |
PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
|
|
EP3529361B1
(en)
|
2016-10-20 |
2021-03-24 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
KR102692556B1
(ko)
|
2017-03-16 |
2024-08-09 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Pd-l1 변이체 면역조절 단백질 및 그의 용도
|
|
CN110662758A
(zh)
|
2017-03-16 |
2020-01-07 |
高山免疫科学股份有限公司 |
Cd80变体免疫调节蛋白及其用途
|
|
WO2018170023A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Pd-l2 variant immunomodulatory proteins and uses thereof
|
|
JP7749319B2
(ja)
|
2017-10-10 |
2025-10-06 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
|
|
PT3697810T
(pt)
|
2017-10-18 |
2026-02-19 |
Alpine Immune Sciences Inc |
Proteínas imunomoduladoras de ligandos icos variantes e composições e métodos relacionados
|
|
BR112020013236A2
(pt)
|
2018-01-03 |
2020-12-01 |
Alpine Immune Sciences, Inc. |
proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
|
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
|
KR20210089146A
(ko)
|
2018-09-19 |
2021-07-15 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
변이체 cd80 단백질 및 관련 구축물의 방법 및 용도
|
|
WO2021181233A2
(en)
|
2020-03-09 |
2021-09-16 |
Pfizer Inc. |
Fusion proteins and uses thereof
|
|
US20250243260A1
(en)
|
2022-03-07 |
2025-07-31 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies and related methods and uses
|